Hart–Scott–Rodino Antitrust Improvements Act

Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease

Retrieved on: 
Monday, December 11, 2023
Stem Cells, Biotechnology, FDA, Health, General Health, Pharmaceutical, Health Technology, Research, Genetics, Science, Clinical Trials, Motivation, Chronic kidney disease, APOL1, Therapy, Complaint, Sanofi, Patient, Hart–Scott–Rodino Antitrust Improvements Act, FTC, Apolipoprotein L1, HSR, Pharmaceutical industry, Pompe

The agreement was originally announced in May 2023 with closing subject to review under the Hart-Scott-Rodino (HSR) Act.

Key Points: 
  • The agreement was originally announced in May 2023 with closing subject to review under the Hart-Scott-Rodino (HSR) Act.
  • “At Maze, our commitment is to the patients around the world that we believe can benefit from our work.
  • With positive preclinical and Phase 1 data, MZE001 has the potential to be the first oral therapeutic option to address Pompe disease, providing a new option for patients suffering from Pompe disease.
  • Maze’s second undisclosed program in chronic kidney disease is scheduled to commence clinical trials in the second half of 2024.

NewMarket Corporation Announces the Acquisition of AMPAC Intermediate Holdings, LLC

Retrieved on: 
Monday, December 4, 2023
Chemicals, Plastics, Other Manufacturing, Aerospace, Manufacturing, Acquisition, Research, Department of Defence, NYSE, Safety, Security (finance), AMPAC, Hart–Scott–Rodino Antitrust Improvements Act, NEU, Annual report, NewMarket Corporation, NASA, Defense, Risk, Halotron I, Ethyl Corporation, Failure, Knowledge, BRX

NewMarket Corporation (NYSE: NEU) today announced its entry into a definitive purchase agreement to acquire AMPAC Intermediate Holdings, LLC, the ultimate parent company of American Pacific Corporation (AMPAC), for approximately $700 million.

Key Points: 
  • NewMarket Corporation (NYSE: NEU) today announced its entry into a definitive purchase agreement to acquire AMPAC Intermediate Holdings, LLC, the ultimate parent company of American Pacific Corporation (AMPAC), for approximately $700 million.
  • AMPAC also manufactures Halotron BrX, a clean and environmentally friendly fire extinguishing agent that replaces legacy high ozone-depleting fire extinguishing agents.
  • The acquisition of AMPAC expands NewMarket’s exposure to mission critical, resilient sectors.
  • NewMarket Corporation, through its subsidiaries Afton Chemical Corporation and Ethyl Corporation, develops, manufactures, blends, and delivers chemical additives that enhance the performance of petroleum products.

Kinder Morgan Announces 2024 Financial Expectations

Retrieved on: 
Monday, December 4, 2023
Energy, Other Energy, Oil, Gas, EBITDA, WTI, Kinder Morgan, NextEra Energy, Acquisition, NYSE, DCF, Pipeline, Henry Hub, CO2, Natural gas, Adjustment, British thermal unit, KMI, West Texas Intermediate, Growth, Hart–Scott–Rodino Antitrust Improvements Act, Fine chemical, Beauty salon

Kinder Morgan, Inc. (NYSE: KMI) today announced its preliminary 2024 financial projections.

Key Points: 
  • Kinder Morgan, Inc. (NYSE: KMI) today announced its preliminary 2024 financial projections.
  • “We are projecting an annualized dividend of $1.15 in 2024, constituting the 7th year in a row in which we have increased our dividend.
  • For descriptions of these non-GAAP financial measures and reconciliations to the most comparable measures prepared in accordance with generally accepted accounting principles, please see “Non-GAAP Financial Measures” below.
  • Kinder Morgan remains committed to transparency and will continue to publish its budget on the company’s website as presented at the investor day conference.

Kite and Arcellx Announce Expansion in Strategic Partnership

Retrieved on: 
Wednesday, November 15, 2023
Research, Hospitals, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Multiple myeloma, Economics, Sparx, ASH, Patient, EPS, IPR, Cancer, Partnership, Lymphoma, BCMA, Hart–Scott–Rodino Antitrust Improvements Act, Pharmaceutical industry, Kite

“Given this, we are deepening our relationship with Arcellx to further support advancement of CART-ddBCMA, bolster our pipeline in multiple myeloma, as well as access opportunities in lymphoma.

Key Points: 
  • “Given this, we are deepening our relationship with Arcellx to further support advancement of CART-ddBCMA, bolster our pipeline in multiple myeloma, as well as access opportunities in lymphoma.
  • In expanding our strategic partnership with Arcellx, we are building upon the established synergy between Arcellx’s platform technologies and Kite’s industry-leading position in CAR T manufacturing and commercialization."
  • “Since entering into this strategic collaboration with Kite almost one year ago, we are thrilled with how the partnership is rapidly progressing and the alignment across our teams,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer.
  • Importantly, these efficiencies embody the trust developed with our Kite partners and do not alter the original agreement in principle or economics.

CF Industries Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Waggaman Ammonia Production Facility Acquisition

Retrieved on: 
Wednesday, November 15, 2023
Agriculture, Natural Resources, Sustainability, Environment, Alternative Energy, Energy, Chemicals, Plastics, Manufacturing, Dyno Nobel, Hand, Economics, CF Industries, NYSE, HSR, IPL, Hart–Scott–Rodino Antitrust Improvements Act, Ammonia

CF Industries Holdings, Inc. (NYSE: CF) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), in connection with its previously announced agreement to purchase Incitec Pivot Limited’s (“IPL”) ammonia production complex located in Waggaman, Louisiana.

Key Points: 
  • CF Industries Holdings, Inc. (NYSE: CF) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), in connection with its previously announced agreement to purchase Incitec Pivot Limited’s (“IPL”) ammonia production complex located in Waggaman, Louisiana.
  • The expiration of the HSR Act waiting period was a condition to the closing of the pending transaction.
  • CF Industries and IPL expect to complete the transaction effective December 1, 2023, subject to the satisfaction of other customary closing conditions.
  • Under the terms of the agreement, CF Industries will purchase the Waggaman ammonia plant and related assets for $1.675 billion.

Splunk Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Transaction With Cisco

Retrieved on: 
Tuesday, November 14, 2023
Data Management, Technology, White House, Federal Government, Security, Other Technology, Apps, Applications, Software, Networks, Internet, Public Policy, Government, Mobile, Wireless, Splunk, Inc., Calendar, CSCO, Hart–Scott–Rodino Antitrust Improvements Act, Cryptocurrency, Pharmaceutical industry, Cisco

Splunk Inc. (NASDAQ: SPLK), the cybersecurity and observability leader, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”), in connection with the previously announced agreement for Splunk to be acquired by Cisco (NASDAQ: CSCO) for $157 per share in cash.

Key Points: 
  • Splunk Inc. (NASDAQ: SPLK), the cybersecurity and observability leader, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”), in connection with the previously announced agreement for Splunk to be acquired by Cisco (NASDAQ: CSCO) for $157 per share in cash.
  • The expiration of the waiting period under the HSR Act occurred at 11:59 p.m. Eastern Time on November 13, 2023.
  • The completion of the merger remains subject to the satisfaction of other closing conditions specified in the merger agreement, including approval of the merger under other applicable antitrust and foreign investment laws and approval by Splunk stockholders.
  • Splunk continues to expect to complete the merger by the end of the third calendar quarter of 2024.

Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Business development, Food, Carcinoma, End-user license agreement, Patient, FDA, Hart–Scott–Rodino Antitrust Improvements Act, DLL3, License, Novartis, Pharmaceutical industry

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement (License Agreement) with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 ( NCT05680922 ).1 The License Agreement grants Novartis the exclusive worldwide rights to develop, manufacture and commercialize these cell therapies, and Novartis may apply its T-Charge™ platform to their manufacture.

Key Points: 
  • Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement (License Agreement) with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 ( NCT05680922 ).1 The License Agreement grants Novartis the exclusive worldwide rights to develop, manufacture and commercialize these cell therapies, and Novartis may apply its T-Charge™ platform to their manufacture.
  • Legend Biotech is initiating clinical development of LB2102 for the treatment of extensive stage small cell lung cancer and large cell neuroendocrine carcinoma after the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application in 2022.
  • “We believe LB2102 has an innovative CAR design and armor mechanism that increases its anti-tumor activity.
  • Under the terms of the License Agreement, Legend Biotech will receive a $100 million upfront payment and will be eligible to receive up to $1.01 billion in clinical, regulatory and commercial milestone payments and tiered royalties.

Academic Partnerships Announces Acquisition of Wiley University Services

Retrieved on: 
Tuesday, November 14, 2023
Winston & Strawn, NYSE, Weil, Gotshal & Manges, Nursing, Student, AP, Centerview Partners, Hart–Scott–Rodino Antitrust Improvements Act, Teaching, University, Learning, Education, Academic Partnerships, Management, Tutoring, Research, DALLAS

DALLAS, Nov. 14, 2023 /PRNewswire/ -- Academic Partnerships ("AP"), a company that assists primarily regional public universities in expanding access and impact by supporting their online programs, announced today that it has entered into a definitive agreement to acquire Wiley University Services, a line of business owned by Wiley (NYSE: WLY). The combined company will support over 125 colleges and universities in 40 U.S. states and internationally.

Key Points: 
  • "Bringing together AP and Wiley University Services will better enable the combined company to help universities meet students where they are with high-quality, timely online education in our rapidly changing world.
  • The combined company will have the resources and expertise to provide best-in-class services to our university partners and their students from diverse backgrounds, including working adults and professionals."
  • Wiley University Services works with institutions to deliver career-connected education programs aimed at helping students achieve their goals.
  • "Wiley University Services' new home with AP will provide the resources to best serve its talented employees and institutional clients," said Wiley Interim CEO Matthew Kissner.

Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Standard BioTools, Hyperion, Genomics, Security (finance), Terrorism, Vii, 600 (number), Supplement, Xi, Health, SBI, Appendix, EBITDA, SomaLogic, News, Form 10-Q, GAAP, Intellectual property, Doctor of Philosophy, Original equipment manufacturer, Research, COVID-19, Risk, Marketing, Annual report, Webcast, Form 10-K, Mass cytometry, Depreciation, Egholm, Standard, Total, Table, Investment, XV, Microfluidics, Hart–Scott–Rodino Antitrust Improvements Act, Failure, Reverse transcription polymerase chain reaction, Fine chemical, Bank, Mergers and acquisitions

As previously announced on October 4, 2023, the Company expects total revenue of $100 million to $105 million for the full year 2023.

Key Points: 
  • As previously announced on October 4, 2023, the Company expects total revenue of $100 million to $105 million for the full year 2023.
  • An explanation of these non-GAAP financial measures is also included below under the heading “Use of Non-GAAP Financial Information.
  • ET, to discuss third quarter 2023 financial results and operational progress as well as to provide additional color on its strategic actions.
  • Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis.

Kinder Morgan to Purchase NextEra Energy Partner’s STX Midstream

Retrieved on: 
Monday, November 6, 2023
Energy, Other Energy, Oil, Gas, Kinder Morgan, HEP, NYSE, Morgan, Dampier to Bunbury Natural Gas Pipeline, PEMEX, NextEra Energy, EBITDA, Eagle Ford, Dallas, Acquisition, Natural Gas Pipeline Company of America, Hand, KMI, Hart–Scott–Rodino Antitrust Improvements Act, LDC, Petroleum, LNG

Kinder Morgan, Inc. (NYSE: KMI) today announced that it has agreed to acquire NextEra Energy Partner’s South Texas assets, STX Midstream, for $1.815 billion.

Key Points: 
  • Kinder Morgan, Inc. (NYSE: KMI) today announced that it has agreed to acquire NextEra Energy Partner’s South Texas assets, STX Midstream, for $1.815 billion.
  • STX Midstream includes a 90% interest in the NET Mexico pipeline; MGI Enterprises, a PEMEX affiliate, owns the other 10%.
  • STX Midstream owns and operates Eagle Ford Midstream, a 158-mile residue line connecting the Eagle Ford basin to the Agua Dulce Hub in Nueces County, Texas.
  • Eagle Ford Midstream is connected to multiple pipeline systems, including KMI’s Tennessee Gas Pipeline, Kinder Morgan Tejas Pipeline and Natural Gas Pipeline Company of America.